{"id":2253,"date":"2020-12-11T10:58:58","date_gmt":"2020-12-11T10:58:58","guid":{"rendered":"http:\/\/www.bioindiaservices.com\/bio3\/?page_id=2253"},"modified":"2023-10-10T10:57:50","modified_gmt":"2023-10-10T10:57:50","slug":"bioindia-news","status":"publish","type":"page","link":"http:\/\/www.bioindiaservices.com\/bio3\/bioindia-news\/","title":{"rendered":"News"},"content":{"rendered":"
\n \n
\n \n \n
\n
\n \n
\n \n
\n
\n \n \n
\n \n
\n \n
\n \n \n

Latest News<\/h1>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n \n
\n \n
\n
\n \n \n
\n \n
\n \n
\n \n

18-Month Below-the-Knee Data with MedAlliance\u2019s SELUTION SLR\u2122 Presented as Late Breaking Trial at VIVA<\/h4><\/a><\/div><\/div>
on<\/span> Oct 8<\/a><\/div><\/div>
8 October 2021 18-month results from the PRESTIGE Below-the-Knee (BTK) study have been presented as a Late Breaking Clinical Trial at VIVA21. The objective of this clinical investigation has been to evaluate safety and performance outcomes of SELUTION SLR\u2122, MedAlliance\u2019s novel sirolimus-eluting balloon, for the treatment of long tibial occlusive […]<\/div><\/div><\/div>
Read more<\/span> <\/path><\/svg><\/span><\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n \n \n

Completion of Enrolment in PRISTINE Registry with SELUTIONSLR\u2122Sirolimus Drug Eluting Balloon<\/h4><\/a><\/div><\/div>
on<\/span> Aug 12<\/a><\/div><\/div>
12 August 2021 MedAlliance has announced completion of patient enrolment in the PRISTINE clinical trial with SELUTION SLR\u2122 018 DEB (drug-eluting balloon) for the treatment of patients with Below-the-Knee (BTK) disease. SELUTION SLR is the first DEB to be awarded \u201cBreakthrough Device Designation\u201d by the FDA. PRISTINE is a Prospective […]<\/div><\/div><\/div>
Read more<\/span> <\/path><\/svg><\/span><\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n \n \n

First Patient Enrolled in SELUTION SLR\u2122SUCCESS PTA Study<\/h4><\/a><\/div><\/div>
on<\/span> Feb 10<\/a><\/div><\/div>
NYON, Switzerland, Feb. 10, 2021 (PRNewswire) MedAlliance has announced enrolment of the first patient in SUCCESS PTA, its large post-market study with the drug-eluting balloon SELUTIONSLRTM for the treatment of patients with peripheral artery disease (PAD). SELUTION SLR is a novel sirolimus-eluting balloon that provides a controlled sustained release of […]<\/div><\/div><\/div>
Read more<\/span> <\/path><\/svg><\/span><\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n \n \n

12-Month Below-the-Knee Data with MedAlliance’s SELUTION SLR\u2122 Presented a Late Breaking Trial at LINC<\/h4><\/a><\/div><\/div>
on<\/span> Jan 28<\/a><\/div><\/div>
NYON, Switzerland, Jan. 28, 2021 (PRNewswire) 12-month results from the PRESTIGE Below-the-Knee (BTK) studyhave been presented as a Late Breaking Trial at LINC 2021. The objective of this clinical investigation has been toevaluate safety and performance outcomes of SELUTION SLRTM,MedAlliance’s novel sirolimus-eluting balloon, for thetreatment of long tibial occlusive lesions […]<\/div><\/div><\/div>
Read more<\/span> <\/path><\/svg><\/span><\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n \n \n

World\u2019s First FDA IDE Coronary Patient Treated With a DEB<\/h4><\/a><\/div><\/div>
on<\/span> Jul 10<\/a><\/div><\/div>
July 10, 2020 (PRNewswire) MedAlliance has announced enrollment of the first patient in its study of SELUTION SLR\u2122 014 DEB for the treatment of In-Stent Restenosis (ISR). This is the first DEB accepted by the FDA for its \u201cBreakthrough Program\u201d.  The SELUTION SLR (Sustained Limus Release) is a novel sirolimus […]<\/div><\/div><\/div>
Read more<\/span> <\/path><\/svg><\/span><\/a><\/span><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div><\/div>\n \n \n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n \n \n
\n \n
\n \n
\n \n
\n
\n \n \n
\n \n
\n \n \n
\n

Copyright \u00a9 BioIndia Services. All Rights Reserved.<\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n<\/div>","protected":false},"excerpt":{"rendered":"

Latest News Copyright \u00a9 BioIndia Services. All Rights Reserved.<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-templates\/full-width-page.php","meta":[],"_links":{"self":[{"href":"http:\/\/www.bioindiaservices.com\/bio3\/wp-json\/wp\/v2\/pages\/2253"}],"collection":[{"href":"http:\/\/www.bioindiaservices.com\/bio3\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"http:\/\/www.bioindiaservices.com\/bio3\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"http:\/\/www.bioindiaservices.com\/bio3\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"http:\/\/www.bioindiaservices.com\/bio3\/wp-json\/wp\/v2\/comments?post=2253"}],"version-history":[{"count":20,"href":"http:\/\/www.bioindiaservices.com\/bio3\/wp-json\/wp\/v2\/pages\/2253\/revisions"}],"predecessor-version":[{"id":11549,"href":"http:\/\/www.bioindiaservices.com\/bio3\/wp-json\/wp\/v2\/pages\/2253\/revisions\/11549"}],"wp:attachment":[{"href":"http:\/\/www.bioindiaservices.com\/bio3\/wp-json\/wp\/v2\/media?parent=2253"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}